News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Genzyme Corporation CEO Open to Sale, Not at $69 a Share
September 1, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BOSTON (Reuters) - Genzyme Corp (GENZ.O) Chief Executive Henri Termeer said he is willing to sell the company he built up over 25 years, but not for $69 a share.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Mergers & acquisitions
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition
February 23, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
February 19, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline
February 18, 2026
·
2 min read
·
Tristan Manalac
Venture capital
Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook
February 18, 2026
·
2 min read
·
Annalee Armstrong
